Company: STAA
Filing Date: 2025-09-16
Form Type: DEFM14A
Source: 0001193125-25-204396
Chunk: 35

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFM14A
Chunk 35
---
 other than STAAR. What should I do? |

| Q: | Who can help answer my questions? |

| A: | If you have any questions concerning the Merger, the Special Meeting or the accompanying proxy statement, would                                           
 like additional copies of the accompanying proxy statement or need help voting your shares of STAAR common stock, please contact STAAR’s proxy solicitor: |

INNISFREE M&A INCORPORATED 501 Madison Avenue, 20th Floor New York, New York 10022 Stockholders, please call toll-free: (877) 750-8233 Banks and brokerage firms, please call: (212) 750-5833 -20-

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS The information covered by this proxy statement may contain forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended (which this proxy statement refers to as the “Securities Act”), and Section 21E of the Exchange Act, as amended by the Private Securities Litigation Reform Act of 1995, such as statements about the consummation of the proposed Merger and the anticipated benefits thereof. Forward-looking statements often contain words such as “anticipate,” “believe,” “expect,” “plan,” “estimate,” “project,” “continue,” “will,” “should,” “may” and similar terms. These forward-looking statements do not constitute guarantees of future performance and are subject to a variety of risks and uncertainties that may cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. In addition, STAAR has based some of these forward-looking statements on assumptions about future events that may prove to be inaccurate. Such factors, risks and uncertainties include:

| • |     | the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger            
 Agreement between the parties to the Merger or extend the anticipated timetable for completion of the proposed transaction; |

| • |     | the failure to obtain the Stockholder Approval; |

| • |     | the failure to obtain certain required regulatory approvals or the failure to satisfy any of the other closing 
 conditions to the completion of the Merger within the expected timeframes or at all;                           |

| • |     | risks related to disruption of management’s attention from STAAR’s ongoing business operations due to 
 the Merger;                                                                                           |

| • |     | disruption from the Merger making it more difficult to maintain